Successful Topline Data from Phase 3 Clinical Trial

Kailera Therapeutics (KLRA) and its Chinese partner, Jiangsu Hengrui Pharmaceuticals (600276.SH), have achieved positive topline data from two Phase 3 clinical trials in China for HRS-7535 (KAI-7535), an oral small-molecule GLP-1 receptor agonist. In a 44-week clinical trial involving obese patients, the highest dose group showed an average weight loss of 9.8%, meeting the primary endpoint. A separate clinical trial targeting patients with diabetes also demonstrated significant blood sugar-lowering efficacy. This is considered a significant achievement, successfully demonstrating the value of its unique pipeline in the next-generation obesity treatment market, which offers maximum convenience with its pill form.

Efficacy Differences and Patient Population Compared to Competing Drugs

The 9.8% weight loss reported in the disclosed data may appear to be slightly lower compared to existing competing products on the market. Novo Nordisk's (NVO) high-dose oral semaglutide recorded approximately 14% weight loss over 64 weeks, and Eli Lilly's (LLY) orforglipron demonstrated approximately 11% weight loss at 72 weeks. However, clinical experts interpret that the lower figures in the Chinese clinical trials are likely due to the relatively lower baseline Body Mass Index (BMI) and a higher proportion of male patients compared to Western populations. Therefore, the actual biological efficacy of the drug is likely to be comparable to that of competing drugs.

High Incidence of Gastrointestinal Adverse Events and Commercial Impact

However, the significant gastrointestinal adverse events observed in the Phase 3 clinical trial are identified as key challenges that must be addressed before market entry. Approximately 70% of patients taking the drug reported nausea, and a high proportion (67% to 69%) experienced vomiting, surprising industry analysts. Even if the pill form offers maximum convenience, if it causes digestive discomfort that patients find difficult to tolerate, long-term compliance will be severely reduced, potentially leading to failure in the market. Therefore, optimizing the timing of drug administration or the dose escalation schedule is essential.

Global Development Strategy Shift Based on Demonstrated Safety

Positively, no signs of liver toxicity, which caused Pfizer (PFE) to discontinue the development of a similar candidate, were observed in this clinical trial. This demonstrates structural stability and is expected to provide a strong safety basis for designing large-scale, multinational Phase 2 and Phase 3 trials, which are preferred by global regulatory agencies such as the FDA. Currently, Kailera Therapeutics (KLRA) is planning to initiate a global Phase 2 trial quickly, incorporating new dosing strategies such as reducing the starting dose and adding a nighttime dosing cohort to lower the incidence of gastrointestinal adverse events to a competitive level (nausea in the 30% range, vomiting below 20%), aiming for market entry in the United States.